**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 86924

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Perilipin2 inhibits the replication of hepatitis B virus deoxyribonucleic acid by regulating autophagy under high-fat conditions**

Wang C *et al*. Plin2 can affect HBV replication

Chuang Wang, Xiao-Yun Gao, Mei Han, Meng-Chun Jiang, Xiao-Yi Shi, Chun-Wen Pu, Xuan Du

**Chuang Wang, Xiao-Yi Shi,** Graduate School, Graduate School of Dalian Medical University, Dalian 116000, Liaoning Province, China

**Xiao-Yun Gao,** Department of Geriatric, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, China

**Mei Han, Meng-Chun Jiang, Xuan Du,** Department of Gastroenterology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, Liaoning Province, China

**Chun-Wen Pu,** Dalian Public Health Clinical Center, Dalian Municipal Research Institute for Public Health, Dalian 116001, Liaoning Province, China

**Co-first authors:** Chuang Wang and Xiao-Yun Gao.

**Co-corresponding authors:** Chun-Wen Pu and Xuan Du.

**Author contributions:** Du X and Gao XY designed the experiment and drafted the manuscript; Wang C performed the experiments; Du X and Wang C participated in the statistical analyses; Han M, Shi XY, and Jiang CM helped draft the manuscript; All authors have read and approved the final manuscript.

**Corresponding author: Xuan Du, PhD, Doctor,** Department of Gastroenterology, The Second Affiliated Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian 116023, Liaoning Province, China. duxuan945@163.com

**Received:** September 11, 2023

**Revised:** October 19, 2023

**Accepted:** November 30, 2023

**Published online:** December 25, 2023

**Abstract**

BACKGROUND

Chronic hepatitis B virus (HBV) infection is often associated with increased lipid deposition in hepatocytes. However, when combined with non-alcoholic fatty liver disease or hyperlipidemia, it tends to have a lower HBV deoxyribonucleic acid (DNA) load. The relationship between lipid metabolism and HBV DNA replication and its underlying mechanisms are not well understood.

AIM

To investigate the relationship between lipid metabolism and HBV DNA replication and its underlying mechanisms.

METHODS

1603 HBsAg-seropositive patients were included in the study. We first explored the relationship between patients' lipid levels, hepatic steatosis, and HBV DNA load. Also, we constructed an HBV infection combined with a hepatic steatosis cell model *in vitro* by fatty acid stimulation of HepG2.2.15 cells to validate the effect of lipid metabolism on HBV DNA replication *in vitro*. By knocking down and overexpressing Plin2, we observed whether Plin2 regulates autophagy and HBV replication. By inhibiting both Plin2 and cellular autophagy under high lipid stimulation, we examined whether the Plin2-autophagy pathway regulates HBV replication.

RESULTS

The results revealed that serum triglyceride levels, high-density lipoprotein levels, and hepatic steatosis ratio were significantly lower in the HBV-DNA high load group. Logistic regression analysis indicated that hepatic steatosis and serum triglyceride levels were negatively correlated with HBV-DNA load. Stratified analysis by HBeAg showed significant negative correlations between HBV-DNA load and hepatic steatosis ratio in both HBeAg-positive and HBeAg-negative groups. An *in vitro* cell model was developed by stimulating HepG2.2.15 cells with palmitic acid and oleic acid to study the relationship between HBV-DNA load and lipid metabolism. The results of the *in vitro* experiments suggested that fatty acid treatment increased lipid droplet deposition and decreased the expression of cell supernatant HBsAg, HBeAg, and HBV DNA load. Western blot and polymerase chain reaction analysis showed that fatty acid stimulation significantly induced Plin2 protein expression and inhibited the expression of hepatocyte autophagy proteins. Inhibition of Plin2 protein expression under fatty acid stimulation reversed the reduction in HBsAg and HBeAg expression and HBV DNA load induced by fatty acid stimulation and the inhibition of cellular autophagy. Knocking down Plin2 and blocking autophagy with 3-methyladenine (3-MA) inhibited HBV DNA replication.

CONCLUSION

In conclusion, lipid metabolism is a significant factor affecting HBV load in patients with HBV infection. The *in vitro* experiments established that fatty acid stimulation inhibits HBV replication *via* the Plin2-autophagy pathway.

**Key Words:** Lipid metabolism; Chronic HBV infection; Nonalcoholic fatty liver; Plin2; Autophagy

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Wang C, Gao XY, Han M, Jiang MC, Shi XY, Pu CW, Du X. Perilipin2 inhibits the replication of hepatitis B virus deoxyribonucleic acid by regulating autophagy under high-fat conditions. *World J Virol* 2023; 12(5): 296-308

**URL**: https://www.wjgnet.com/2220-3249/full/v12/i5/296.htm

**DOI**: https://dx.doi.org/10.5501/wjv.v12.i5.296

**Core Tip:** Our data suggest that fatty acid stimulation inhibits hepatitis B virus (HBV) replication by upregulating Plin2 expression, inhibiting hepatocyte autophagy. This process associates with lipid metabolism, autophagy pathway, and HBV replication. Further study of lipid metabolism-Plin2-autophagy is important to understand HBV host interactions and pathogenesis better and suggests a possible route for treating patients with chronic HBV infection combined with nonalcoholic fatty liver disease.

**INTRODUCTION**

Hepatitis B virus (HBV) infection is a global health issue[1]. According to the World Health Organization, about one-third of the world's population will contract acute HBV at some point in their life[2]. Current main treatments include nucleoside analogs and interferon; however, they are not effective in eliminating the virus[3]. Therefore, it is imperative to better understand the underlying mechanisms behind HBV infection-induced disease to find new targets for anti-HBV therapy.

The relationship between HBV infection and lipid metabolism has received more attention in the last decade. Clinical studies have demonstrated that chronic HBV infection enhances the incidence of nonalcoholic fatty liver disease (NAFLD), with NAFLD co-infected with HBV accounting for 13.5% of all HBV patients[4]. These studies indicate a close association between HBV infection and altered lipid metabolism. This present study intends to clarify the mechanism of why increased lipid deposition in the liver can also inhibited HBV replication in hepatocytes[5].

Autophagy is an evolutionarily conserved catabolic process that regulates HBV replication and is required to maintain cellular homeostasis in response to the microenvironment. It involves selective and non-selective mechanisms that cause intracellular substrate degradation[6]. HBV was found to be able to maintain its own replication by inducing hepatocyte autophagy, and when cellular autophagy was inhibited, HBV replication expression in hepatocytes was significantly reduced[7]. Perilipin2 (Plin2) is involved in the formation of lipid droplets in the liver and peripheral tissues[8]. Plin2 is highly upregulated in humans and rodents with NAFLD[5,9]. Purposeful knockdown of Plin2 protein in the mouse liver was found to significantly reduce liver weight, body weight, and adipose tissue mass[10]. In a previous study on NAFLD pathogenesis, it was found that Plin2 is not only involved in intracellular lipid deposition but also regulates intracellular autophagy, and stimulation of hepatocytes with high concentrations of fatty acids results in increased Plin2 expression and cellular autophagy inhibition[11].

Combined with the above, we speculated that the Plin2-autophagy pathway might be involved in regulating lipid deposition and HBV replication in hepatocytes. In this study, we first explored the relationship between patients' lipid levels, hepatic steatosis, and HBV deoxyribonucleic acid (DNA) load. Also, we constructed an HBV infection combined with a hepatic steatosis cell model *in vitro* by fatty acid stimulation of HepG2.2.15 cells to validate the effect of lipid metabolism on HBV DNA replication *in vitro*. By knocking down and overexpressing Plin2, we observed whether Plin2 regulates autophagy and HBV replication. By inhibiting both Plin2 and cellular autophagy under high lipid stimulation, we examined whether the Plin2-autophagy pathway regulates HBV replication. This present study intends to investigate the relationship between lipid metabolism and HBV replication through retrospective analysis and *in vitro* studies, providing a novel theoretical basis for the mechanism of HBV replication and a new target for searching new therapeutic sites.

**MATERIALS AND METHODS**

***Ethical statement***

The study has been approved by the Ethics Committee of Dalian Sixth People's Hospital. The privacy rights of human subjects were always respected during human experimentation, and informed consent was obtained prior to the experiment. The ethics program number is DLY/CB-IRB-026.

***Patient selection***

In this cross-sectional hospital-based study, all patients were recruited from the Dalian Sixth People's Hospital. A total of 1603 HBsAg-positive patients underwent a comprehensive health examination with no prior antiviral treatments to evaluate the effect of lipid profile on HBV viral replication. Additionally, 132 chronic hepatitis B patients were included in the study to investigate the effect of antiviral treatment on lipid profile. Patients with hepatitis C and D, autoimmune hepatitis, alcoholic fatty liver, Wilson's disease, drug-related hepatic steatosis, liver surgery, or liver transplantation were excluded from the study.

***Clinical data collection***

During the study, data on age, sex, alcohol consumption, and medical history were collected through face-to-face interviews. Following an overnight fast, blood samples were obtained from all participants. HBsAg, antibodies against HBsAg, HBeAg, antibodies against HBeAg, and antibodies against hepatitis B core antigen were measured using an immunoassay analyzer. The levels of serum HBV-DNA copy were measured using the COBAS Amplicor HBV monitor test (Cap/ctm, Roche, Switzerland). Clinical chemistry systems were used to evaluate the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase, total bile acids, total bilirubin, albumin, and bile acid.

***Reagents and antibodies***

The HBV-producing HepG2.2.15 hepatoma cell line with an integrated HBV genomic dimer was obtained from the Chinese Academy of Sciences (CAS) in Beijing, China. Trypsin-EDTA (#27250–018), fetal bovine serum (#10100147), phosphate-buffered saline (PBS) (#226013), Opti MEM medium (#22600134), and Dulbecco's modified essential medium (DMEM) (#31600083) were purchased from GIBCO BRL (Grand Island, NY, United States). Oleic acid (OA, #15724), palmitic acid (PA, #27567713), and 3-methyladenine (3MA, #M9281) were acquired from Sigma-Aldrich (Missouri, United States). Perilipin2 (Plin2, #ac219686) was obtained from Abcam Technologies (Abcam, Cambridge, United Kingdom). Light chain 3 (LC3, #A11280), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, #AC002), anti-rabbit IgG (#AS014), and anti-mouse IgG (#LV-AS003) were obtained from Wuhan Abcotec Biotechnology Co Ltd (Abclonal, Wuhan, China).

***Cell line, plasmid, and transfection***

HepG2.2.15 cells were obtained from the CAS and cultured in T25 cell culture flasks with 10% heat-inactivated fetal bovine serum (GIBCO BRL) (#10100147), antibiotics, and high glucose DMEM (GIBCO) (#31600083). The flasks were pre-cultured at 37°C for 18-24 h in a 5% CO2 incubator.

Plin2 knockdown and overexpression plasmids were synthesized by Suzhou Jima Bio. Plasmid transfection was performed following the manufacturer's instructions for Lipofectamine 2000 transfection reagent (Invitrogen).

***Western blotting***

Whole-cell protein extracts were obtained by passive cell lysis using protease and phosphorylated protease inhibitors following the manufacturer's instructions, and protein concentrations were determined using the BCA method. SDS-PAGE (10% gel) was used to separate samples containing approximately 30 µg of protein per well, and the proteins were transferred to PVDF membranes, which were incubated with primary antibody at 4°C overnight after being closed in low-fat milk powder for 2 h at room temperature in TBST. The membranes were washed and placed in BLOTTO containing secondary antibodies (HRP-labeled goat anti-rabbit antibody) for 1.5 h at room temperature. Following TBST clearing, the membranes were placed in the chromogen for 30 s and exposed immediately to the exposure cassette. The method was to estimate the ratio of the brightness value of each sample strip to the brightness value of the corresponding GAPDH (internal reference) strip to get the corrected strip brightness value.

***Triglyceride content detection***

The triglyceride content of HepG2.2.15 was measured using the Triglyceride Quantification Assay Kit (Abcam) for colorimetric detection, following the manufacturer's protocol.

***Real-time quantitative polymerase chain reaction analysis of mRNA expression***

Several methods have been described for the detection of HBV daughter DNA in culture supernatants[12,13]. Real-time reverse transcription (RT) polymerase chain reaction (PCR) assay using primers 5'TCTTGCCTTACTTTTGGAAG 3' (forward) 5'AGTTCTTCTTCTTCTAGGGGACC3' (reverse) were used to measure HBV pgRNA and Plin2 mRNA levels in cells.

***Assays to detect HBsAg and HBeAg in the cell culture supernatant***

HBsAg and HBeAg levels were evaluated using a commercial ELISA kit (Hunan Shengxiang Biotechnology Co., Ltd., Hunan, China) following the manufacturer's instructions. The absorbance of each well was sequentially measured at 450 nm wavelength with zero blank air conditioning for the final assay.

***Oil red staining***

After stimulating HepG2.2.15 cells with free fatty acids, the cells were rinsed three times with PBS and fixed in 10% formalin for 15 min at room temperature. Following fixation, the cells were stained with Oil Red O for 20 min at room temperature. Stained cells were observed by a fluorescent microscope (Leica DMI 4000 B) on the white light setting (magnification, ×100).

***GFP-LC3 fluorescence analysis***

After preincubation in a complete medium at 37°C in 21% O2 and 5%CO2 for 24 h, the cells were transfected with GFP-LC3 following the manufacturer's instructions to monitor autophagy flux. After 8 h of transfection, the cells were rinsed with PBS; a complete culture medium was added to the cells. Finally, the samples were observed under a fluorescence microscope (Nikon, Tokyo, Japan)

***Statistical analyses***

Continuous variables were reported as mean ± standard deviation or median (interquartile range). Dependent variables were expressed as numbers or percentages. The Wilcoxon matched-pairs signed-rank test, a nonparametric statistical test, was employed to compare non-normally distributed continuous data. This test was used to analyze various variables, including age, gender, FBG, ALT, AST, ALP, γ-GGT, LDH, bile acids, total cholesterol, triglycerides, HDL-C, LDL-C, apoA, and apoB. Chi-square test was used to compare the differences in hepatic steatosis prevalence and the HBeAg sero-positive prevalence of patients with high or low HBV DNA load. Binary logistic regression analysis was conducted to identify potential factors influencing HBV DNA load, such as hepatic steatosis, triglycerides, apoA, apoB, cholesterol, HDL-C, and LDL-C. Statistical analysis was performed using IBM Corp's SPSS version 24.0 software. A two-sided *P* value < 0.05 was considered statistically significant. All experiments were conducted in triplicates, and western blot data were analyzed using *t*-tests.

**RESULTS**

***Clinical characteristics of HBsAg-seropositive participants***

In this study, 1603 HBsAg-seropositive patients were included, of which 674 (42.0%) were HBeAg-seropositive. Of the total patients, 1015 (63.3%) were male, and 815 (50.8%) had a high HBV viral load, defined as serum HBV DNA levels > 104 copies/mL. The median age was 52 years (range 43–60). Table 1 presents the characteristics of the HBsAg-seropositive patients. Patients in the high HBV DNA group had a higher levels of ALT, AST, ALP, γ-GGT, LDH, and HDL-C, and lower levels of triglyceride (TG), FBG, albumin, LDL-C, and apoB compared to those in the low HBV DNA group (*P* < 0.05). However, there were no significant differences between the two groups with regards to TC, total bilirubin, and apoA. The characteristics of the HBeAg-seropositive patients are shown in Table 2.

***Clinical characteristics of HBeAg-seropositive and HBeAg-seronegative patients***

Out of the 1603 HBsAg-seropositive patients, 661 were HBeAg-seropositive and 942 were HBeAg-seronegative. Among the HBeAg-seropositive group, 460 (69.6%) patients had a high viral load while in the HBeAg-seronegative group, 355 (37.7%) patients had a high viral load. Patients with high viral loads in the HBeAg-seropositive group had higher levels of ALT, AST, and HDL-C, and lower levels of albumin, FBG, LDL-C, apoB, and a lower ratio of steatosis (*P* < 0.05) (Table 1). In contrast, patients with high viral loads in the HBeAg-seronegative group had higher levels of ALT, AST, ALP, albumin, total bilirubin, and bile acid, and lower levels of TC, LDL-C, apoB, γ-GGT, TG, and a lower ratio of steatosis (*P* < 0.05) (Table 2).

***Metabolic factors associated with HBV-DNA load in the HBsAg-seropositive participants***

Table 3 presents the results of binary logistic regression analyses of metabolic factors associated with HBV-DNA load. The serum levels of TG (OR 0.83, 95%CI 0.70–0.98, *P* = 0.027), apoA (OR 0.47, 95%CI 0.26–0.83, *P* = 0.009), and LDL-C (OR 0.59, 95%CI 0.45–0.77, *P* < 0.001) were negatively associated with HBV-DNA load, while hepatic steatosis (OR 0.15, 95%CI 0.10–0.23, *P* < 0.001) was also negatively associated with HBV-DNA load. On the other hand, TC level (OR 1.39, 95%CI 1.09–1.77, *P* = 0.009) was positively associated with HBV-DNA load.

***Metabolic factors associated with HBV-DNA load in HBeAg-seropositive and HBeAg-seronegative participants***

Table 3 provides the results of logistic regression analyses of metabolic factors associated with HBV-DNA load in HBeAg-seropositive and HBeAg-seronegative patients. In HBeAg-seropositive patients, serum LDL-C level (OR 0.38, 95%CI 0.24–0.60, *P* < 0.001) and hepatic steatosis (OR 0.11, 95%CI 0.05–0.22, *P* < 0.001) were negatively associated with HBV-DNA load, while TC level (OR 2.33, 95%CI 1.55–3.51, *P* < 0.001) was positively associated with HBV-DNA load. In contrast, in HBeAg-seronegative patients, serum TG level (OR 0.69, 95%CI 0.55–0.87, *P* = 0.002), LDL-C level (OR 0.46, 95%CI 0.31–0.67, *P* < 0.001), and hepatic steatosis (OR 0.19, 95%CI 0.11–0.35, *P* < 0.001) were negatively associated with HBV-DNA load, while TC level (OR 1.69, 95%CI 1.19–2.40, *P* = 0.004) was positively associated with HBV-DNA load.

***In vitro high-fat conditions inhibit the replication of HBV DNA***

To investigate the relationship between lipid metabolism and HBV DNA replication *in vitro*, HepG2.2.15 cells were stimulated with varying concentrations of PA and oleic OA to create a model of HBV infection combined with hepatic steatosis. Real-time PCR was used to detect changes in HBV DNA replication levels. The results demonstrated that the expression load of HBV DNA significantly decreased in a concentration-dependent manner with the increase of PA or OA concentration (Figure 1A and B). The optimal stimulation concentration of OA was 0.2 M, while the optimal stimulation concentration of PA was 100 μmol/L. The optimal fatty acid concentrations were prepared into free fatty acids (FFA) at an OA:PA ratio of 2:1. After 72 h of FFA treatment, HepG2.2.15 cells were stained with oil red O hematoxylin, revealing a significant increase in intracellular lipid droplets in the FFA group compared to the control group, and fusion phenomena were observed (Figure 1C). The intracellular TG content was higher in the high-fat stimulation conditions than in the control group (Figure 1D). ELISA was used to measure HBsAg and HBeAg levels in cell culture supernatants, and it was found that high-fat stimulation inhibited the expression of both HBsAg (Figure 1E) and HBeAg (Figure 1F).

Based on these findings, it can be concluded that high-fat conditions inhibit the expression of HBV DNA and its serum markers in a concentration-dependent manner. However, the exact mechanism underlying this inhibition remains unclear.

***Fatty acids stimulation promoted the expression of Plin2 and inhibited the replication of HBV DNA***

To investigate the role of Plin2 in inhibiting HBV replication under high lipid conditions, we performed both Plin2 knockdown and overexpression experiments in HepG2.2.15 cells after fatty acid stimulation. After downregulating Plin2 protein, the number and volume of intracellular lipid droplets significantly decreased in both the control group and FFA-stimulated group under microscopy, whereas the number of lipid droplets increased in the Plin2 overexpression group (Figure 2A). Additionally, TG content was observed to increase in the Plin2 overexpression group (Figure 2B and C). HBV DNA load increased significantly after knockdown of Plin2 (Figure 2D-F). The expression of HBsAg and HBeAg was also significantly upregulated after transfection with siPlin2 plasmid, whereas the expression of both markers was downregulated after overexpression of Plin2 (Figure 2G-J).

These findings suggest that high lipid conditions upregulate Plin2 expression and that Plin2 plays a role in counteracting the regulation of lipid metabolism.

***Plin2 affects HBV DNA replication by regulating autophagy***

Western blotting was used to examine the expression of Plin2 and autophagy-related proteins LC3-II and LC3-I. The results showed that Plin2 expression was significantly upregulated under fatty acid stimulation conditions, and Plin2 knockdown under fatty acid stimulation conditions demonstrated a decreasing trend in upregulated Plin2 expression (Figure 3A-C). Autophagy-related proteins LC3-II/LC3-I were significantly decreased when HepG2.2.15 cells were stimulated with fatty acids, indicating autophagy inhibition. Autophagy expression increased when Plin2 expression was disturbed; after knockdown of Plin2 under high-fat conditions, autophagy was restored, whereas overexpression of Plin2 under both normal medium and high-fat stimulation significantly inhibited autophagy (Figure 3B and D). The number of autophagic vesicles significantly decreased when HepG2.2.15 cells were stimulated with fatty acids, indicating that autophagy was inhibited as seen through GFP-LC3 staining. The number of autophagic vesicles increased when Plin2 expression was interfered with and significantly decreased when Plin2 expression was overexpressed (Figure 3E).

Based on these findings, it can be concluded that fatty acid stimulation alters the autophagic trend by affecting the expression of Plin2, thereby affecting HBV DNA replication.

***Lipid metabolism affects HBV DNA replication through Plin2autophagy-related pathway***

Plin2 knockdown under fatty acid stimulation was observed to restore the inhibited HBV replication, whereas the restored DNA expression load was again inhibited after adding 3-MA to inhibit autophagy (Figure 3F). Plin2 protein expression remained unchanged upon the addition of autophagy inhibitor, as observed through Western blot analysis (Figure 3G and H). In contrast, the values of autophagy-related protein LC3-II/LC3-I were significantly downregulated (Figure 3G and I), indicating that autophagy was clearly inhibited. These results suggest that fatty acid stimulation inhibits autophagy and HBV DNA replication *via* Plin2.

**DISCUSSION**

HBV, a DNA virus that causes immune-mediated liver disease, can be transmitted through blood and body fluids. Although immunomodulatory drugs such as interferon and antiviral drugs have a good safety profile and are also effective in controlling HBV replication in patients with chronic hepatitis B, they rarely eliminate HBV completely and do not completely eliminate liver cancer risk[14]. Therefore, there is an urgent requirement to explore the deeper regulatory mechanisms of HBV in order to seek the development of new drugs for HBV clearance.

Hepatic steatosis is characterized by an excessive accumulation of triglycerides in hepatocytes[15]. In previous studies, hepatic steatosis has been found in patients with chronic HBV infection, causing a reduction in their response to antiviral therapy[16]. However, there is mixed evidence on the association between hepatic steatosis and HBV replication. Several studies have shown that hepatic steatosis induces HBsAg clearance and reduces HBV replication[17,18]. Chia-Ming Chu's study showed that in patients with increased body mass index, hepatic steatosis accelerated HBsAg serological clearance by approximately 5 years[19]. Conversely, Lesmana *et al*[20] found no difference in HBV replication between HBV patients with and without hepatic steatosis. Our results indicated that serum triglycerides, HDL levels, and the rate of hepatic steatosis were significantly lower in the HBV-DNA high load (815 cases) group compared to the HBV-DNA low load (788 cases) group. The findings of logistic regression demonstrated that serum TG levels (OR 0.83 95%CI 0.70–0.98, *P* = 0.027), apoA levels (OR 0.47, 95%CI 0.26–0.83, *P* = 0.009), LDL-C levels (OR 0.59, 95%CI 0.45–0.77, *P <* 0.001) and hepatic steatosis (OR 0.15, 95%CI 0.10–0.23, *P <* 0.001) showed significant negative correlation with HBV-DNA load. As a result, we conducted a stratified analysis according to HBeAg serostatus. The results of logistic regression showed that hepatic steatosis serum triglyceride load was negatively correlated with blood HBV-DNA load in both HBeAg positive or negative groups (*P* < 0.001). These findings are consistent with a study reported by Jarcuska *et al*[21], which stated a significantly lower HBV-DNA load in patients with hypertriglyceridemia. These findings indicate that increased lipid metabolism in the body can inhibit HBV replication.

Previous studies have demonstrated that autophagy is closely associated with HBV DNA replication, and various factors in HBV infection, such as interferon Alpha and endoplasmic reticulum stress, can affect HBV replication by inducing autophagy[22]. Yongjun Tian *et al*[23] found that after liver-specific Atg5 knockdown in the HBV Tg05 mouse, the serum levels of HBeAg and HBsAg were decreased by about 50% and 60%, respectively. However, this autophagy inhibition decreased HBV DNA levels by more than 90%. A previous study showed that IFNα-2a treatment promoted autophagy initiation and blocked autophagy degradation, leading to a slight enhancement of HBV replication[24]. Autophagy disorders often result in metabolic abnormalities and play an essential role in the pathogenesis of numerous metabolic liver diseases, such as alcoholic liver disease and NAFLD[25]. Singh *et al*[26] coined the term "lipophagy" after identifying autophagy-mediated lipolytic functions in the LIPA pathway; TSAI T H showed that specific knockdown of Plin2 decreased triglyceride levels in mice by approximately 60%[27]. In another study of liver-specific Plin2 knockout mice, a significant increase in LC3 and p62-positive spots were detected in the livers of Plin2-deficient mice fed WTD[28]. In the study by Tsai *et al*[27], it was found that the down-regulation of Plin2 stimulated TG catabolism by upregulating autophagy expression through direct knockdown of Plin2. Therefore, we speculated that the high-fat environment regulates the Plin2-autophagy pathway and thus inhibits HBV DNA replication. Our experiments first examined the relationship between Plin2 and autophagy. Autophagy expression increased both under normal medium and under high-fat stimulation when Plin2 protein expression was down-regulated, and overexpression of Plin2 protein resulted in significant inhibition of autophagy. Fluorescence microscopy showed an increase in autophagy vesicles when Plin2 protein expression was down-regulated. Then the association between Plin2 and autophagy under fatty acid stimulation was further explored. Plin2 expression was significantly upregulated in HepG2.2.15 cells, and cellular autophagy was significantly inhibited. Compared to the control group, the expression of supernatant HBV DNA load and serological markers in HepG2.2.15 cells were significantly lower in the Plin2 knockdown group, whereas the overexpression of Plin2 was reversed. Finally, we inhibited the growth of autophagy with 3-MA in parallel with the knockdown of Plin2. At that time, we found that the growth of autophagy-related proteins was significantly reduced. In addition, the increased HBV DNA replication was also reduced, and HBsAg and HBeAg were similarly altered. All these results indicate that the Plin2-autophagy pathway is involved in the regulation of high-fat inhibition of HBV replication.

**CONCLUSION**

In summary, our data suggest that fatty acid stimulation inhibits HBV replication by upregulating Plin2 expression, inhibiting hepatocyte autophagy. This process associates with lipid metabolism, autophagy pathway, and HBV replication. Further study of lipid metabolism-Plin2-autophagy is important to understand HBV host interactions and pathogenesis better and suggests a possible route for treating patients with chronic HBV infection combined with NAFLD.

**ARTICLE HIGHLIGHTS**

***Research background***

The relationship between lipid metabolism and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) replication and its underlying mechanisms are not well understood.

***Research motivation***

To investigate the relationship between lipid metabolism and HBV DNA replication and its underlying mechanisms.

***Research objectives***

We speculated that the Plin2-autophagy pathway might be involved in regulating lipid deposition and HBV replication in hepatocytes.

***Research methods***

We first explored the relationship between patients' lipid levels and HBV DNA load. Also, we constructed an HBV infection combined with a hepatic steatosis cell model *in vitro.*

***Research results***

Stratified analysis by HBeAg showed significant negative correlations between HBV-DNA load and hepatic steatosis ratio in both HBeAg-positive group and in HBeAg-negative group. The results of *in vitro* experiments suggested that fatty acid treatment increased the lipid droplets deposition and decreased the cell supernatant HBsAg, HBeAg expression and HBV DNA load.

***Research conclusions***

Fatty acid stimulation inhibits HBV replication by upregulating Plin2 expression, inhibiting hepatocyte autophagy.

***Research perspectives***

A possible route for treating patients with chronic HBV infection combined with nonalcoholic fatty liver disease.

**ACKNOWLEDGEMENTS**

Thank you, Professor Song Guirong, for your support in the statistical design of our experiment.

**REFERENCES**

1 **Zhang WL**, Ji ZH, Fu T, Zhang L, Su HX, Yan YP. [Meta analysis on HBsAg-positive rate among general populations aged 1-59 years, 2007-2016, China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2017; **38**: 1278-1284 [PMID: 28910947 DOI: 10.3760/cma.j.issn.0254-6450.2017.09.027]

2 **Iannacone M**, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. *Nat Rev Immunol* 2022; **22**: 19-32 [PMID: 34002067 DOI: 10.1038/s41577-021-00549-4]

3 **European Association for the Study of the Liver.** European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

4 **Wong VW**, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Chan HY, Woo J, Chan FK, Chan HL. Hepatitis B virus infection and fatty liver in the general population. *J Hepatol* 2012; **56**: 533-540 [PMID: 22027575 DOI: 10.1016/j.jhep.2011.09.013]

5 **Itabe H**, Yamaguchi T, Nimura S, Sasabe N. Perilipins: a diversity of intracellular lipid droplet proteins. *Lipids Health Dis* 2017; **16**: 83 [PMID: 28454542 DOI: 10.1186/s12944-017-0473-y]

6 **Chiramel AI**, Best SM. Role of autophagy in Zika virus infection and pathogenesis. *Virus Res* 2018; **254**: 34-40 [PMID: 28899653 DOI: 10.1016/j.virusres.2017.09.006]

7 **Xie M**, Yang Z, Liu Y, Zheng M. The role of HBV-induced autophagy in HBV replication and HBV related-HCC. *Life Sci* 2018; **205**: 107-112 [PMID: 29709654 DOI: 10.1016/j.lfs.2018.04.051]

8 **Takahashi Y**, Shinoda A, Kamada H, Shimizu M, Inoue J, Sato R. Perilipin2 plays a positive role in adipocytes during lipolysis by escaping proteasomal degradation. *Sci Rep* 2016; **6**: 20975 [PMID: 26876687 DOI: 10.1038/srep20975]

9 **Zhang X**, Wang Y, Liu P. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease. *Protein Cell* 2017; **8**: 4-13 [PMID: 27757845 DOI: 10.1007/s13238-016-0327-9]

10 **Najt CP**, Senthivinayagam S, Aljazi MB, Fader KA, Olenic SD, Brock JR, Lydic TA, Jones AD, Atshaves BP. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2016; **310**: G726-G738 [PMID: 26968211 DOI: 10.1152/ajpgi.00436.2015]

11 **Fader Kaiser CM**, Romano PS, Vanrell MC, Pocognoni CA, Jacob J, Caruso B, Delgui LR. Biogenesis and Breakdown of Lipid Droplets in Pathological Conditions. *Front Cell Dev Biol* 2021; **9**: 826248 [PMID: 35198567 DOI: 10.3389/fcell.2021.826248]

12 **Lin Y**, Deng W, Pang J, Kemper T, Hu J, Yin J, Zhang J, Lu M. The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy. *Cell Microbiol* 2017; **19** [PMID: 27886437 DOI: 10.1111/cmi.12709]

13 **Zhang X**, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. *Hepatology* 2011; **53**: 1476-1485 [PMID: 21520166 DOI: 10.1002/hep.24195]

14 **Udompap P**, Kim WR. Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. *Clin Liver Dis (Hoboken)* 2020; **15**: 85-90 [PMID: 32226623 DOI: 10.1002/cld.904]

15 **Idilman IS**, Ozdeniz I, Karcaaltincaba M. Hepatic Steatosis: Etiology, Patterns, and Quantification. *Semin Ultrasound CT MR* 2016; **37**: 501-510 [PMID: 27986169 DOI: 10.1053/j.sult.2016.08.003]

16 **Jin X**, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. *PLoS One* 2012; **7**: e34198 [PMID: 22479562 DOI: 10.1371/journal.pone.0034198]

17 **Hui RWH**, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, Wong DK, Lai CL, Yuen MF. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. *J Viral Hepat* 2018; **25**: 97-104 [PMID: 28772340 DOI: 10.1111/jvh.12766]

18 **Machado MV**, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. *J Gastroenterol Hepatol* 2011; **26**: 1361-1367 [PMID: 21649726 DOI: 10.1111/j.1440-1746.2011.06801.x]

19 **Chu CM**, Lin DY, Liaw YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. *Dig Dis Sci* 2013; **58**: 275-281 [PMID: 22903182 DOI: 10.1007/s10620-012-2343-9]

20 **Lesmana LA**, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. *Acta Med Indones* 2012; **44**: 35-39 [PMID: 22451183]

21 **Jarčuška P**, Janičko M, Kružliak P, Novák M, Veselíny E, Fedačko J, Senajová G, Dražilová S, Madarasová-Gecková A, Mareková M, Pella D, Siegfried L, Kristián P, Kolesárová E; HepaMeta Study Group. Hepatitis B virus infection in patients with metabolic syndrome: a complicated relationship. Results of a population based study. *Eur J Intern Med* 2014; **25**: 286-291 [PMID: 24445023 DOI: 10.1016/j.ejim.2014.01.006]

22 **Chen Q**, Fang W, Cui K, Chen Q, Xiang X, Zhang J, Zhang Y, Mai K, Ai Q. Endoplasmic reticulum stress induces hepatic steatosis by transcriptional upregulating lipid droplet protein perilipin2. *FASEB J* 2021; **35**: e21900 [PMID: 34547130 DOI: 10.1096/fj.202100739RR]

23 **Tian Y**, Sir D, Kuo CF, Ann DK, Ou JH. Autophagy required for hepatitis B virus replication in transgenic mice. *J Virol* 2011; **85**: 13453-13456 [PMID: 21957292 DOI: 10.1128/JVI.06064-11]

24 **Li J**, Kemper T, Broering R, Chen J, Yuan Z, Wang X, Lu M. Interferon Alpha Induces Cellular Autophagy and Modulates Hepatitis B Virus Replication. *Front Cell Infect Microbiol* 2022; **12**: 804011 [PMID: 35186790 DOI: 10.3389/fcimb.2022.804011]

25 **Byrnes K**, Blessinger S, Bailey NT, Scaife R, Liu G, Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. *Acta Pharm Sin B* 2022; **12**: 33-49 [PMID: 35127371 DOI: 10.1016/j.apsb.2021.07.021]

26 **Singh R**, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. *Nature* 2009; **458**: 1131-1135 [PMID: 19339967 DOI: 10.1038/nature07976]

27 **Tsai TH**, Chen E, Li L, Saha P, Lee HJ, Huang LS, Shelness GS, Chan L, Chang BH. The constitutive lipid droplet protein PLIN2 regulates autophagy in liver. *Autophagy* 2017; **13**: 1130-1144 [PMID: 28548876 DOI: 10.1080/15548627.2017.1319544]

28 **Sir D**, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. *Proc Natl Acad Sci USA* 2010; **107**: 4383-4388 [PMID: 20142477 DOI: 10.1073/pnas.0911373107]

**Footnotes**

**Institutional review board statement:** The study has been approved by the Ethics Committee of Dalian Sixth People's Hospital. The privacy rights of human subjects were always respected during human experimentation, and informed consent was obtained prior to the experiment. The ethics program number is DLY/CB-IRB-026.

**Institutional animal care and use committee statement:** This study does not involve animal experiments.

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 11, 2023

**First decision:** October 9, 2023

**Article in press:** November 30, 2023

**Specialty type:** Cell biology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Spera AM, Italy; Kelleni MT, Egypt **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Zhang XD


**Figure Legends**

****

**Figure 1 *In vitro*, high lipid cases promote lipid droplet formation and inhibit chronic hepatitis B virus deoxyribonucleic acid replication and the choreographing of related antibodies.** A and B: HepG2.2.15 cells were stimulated with different concentrations of palmitic acid (PA) and oleic acid (OA) for 48 h, and the expression of chronic hepatitis B virus deoxyribonucleic acid was detected; C: 0.2 mmol/L concentration of OA and 100 μmol/L concentration of PA were applied to stimulate HepG2.2.15 cells for 48 h, and the intracellular lipid droplet formation was detected by applying oil red O staining method; D: Detection of intracellular triglyceride content in both groups; E and F: After applying free fatty acids stimulation for 48 h, the levels of HBsAg and HBeAg secreted by the two groups of cells were detected by the ELISA method, respectively. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. NC: Nucleocapsid protein; FFA: Free fatty acids.

****

**Figure 2 To investigate the role of Plin2 in the effect of high-lipid conditions on chronic hepatitis B virus.** A: Oil red O staining to observe lipid droplet formation; B and C: Triglyceride (TG) assay kit was applied to detect the TG content of each group; D-F: Quantitative polymerase chain reaction method was applied to detect the chronic hepatitis B virus deoxyribonucleic acid content in each group; G-J: HBsAg and HBeAg levels were detected in each group by the ELISA method. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001.

****

**Figure 3 Abnormal lipid metabolism affects chronic hepatitis B virus deoxyribonucleic acid replication through the Plin2-autophagy-related pathway.** A: Quantitative polymerase chain reaction (q-PCR) method was applied to detect Plin2 mRNA levels; B-D: Western blot to detect the expression of Plin2 and LC3 in each group and detect the grayscale value; E: GFP-LC3 formation was observed under the fluorescence microscope; F: Chronic hepatitis B virus deoxyribonucleic acid levels were detected by applying q-PCR; G-I: Western blot was performed to detect the expression of Plin2 and LC3 in each group and to detect the grayscale values. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001.

**Table 1 Demographic, clinical, and laboratory characteristics of HBsAg-positive patients with high and low viral load using 104 copies per mL as the cutoff point, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factors** | **ALL** | **High HBV DNA** | **Low HBV DNA** | ***P*** **value** |
| **Case *n* = 1603** | **Case *n* = 815** | **Case *n* = 788** |
| **Demographic** |  |  |  |  |
| Age (yr) | 52 (43–60) | 51 (40–60) | 53 (45–61) | 0.010 |
| Male gender | 1015 (63.28) | 131 (69.6) | 401 (68.2) | 0.703 |
| **Laboratory tests** |  |  |  |  |
| FBG (mmol/L) | 5.10 (4.61–5.87) | 5.00 (4.5–5.7) | 5.21 (4.77–6.00) | < 0.001 |
| ALT (U/L) | 47.95 (25.00–109.92) | 68.3 (37.1–155.83) | 31.7 (20.3–67.7) | < 0.001 |
| AST (U/L) | 41.19 (25.00–81.97) | 52.95 (33.33–106.8) | 29.86 (21.31–55.55) | < 0.001 |
| ALP (U/L) | 81.40 (63.63–109.00) | 85.30 (66.00–116.60) | 76.65 (61.9–104.00) | 0.003 |
| γ-GGT (U/L) | 51.20 (22.89–113.36) | 60.00 (29.13–135.00) | 41.60 (18.97–100.12) | 0.038 |
| LDH (U/L) | 194.8 (170.23–231.10) | 196.00 (171.56–239.00) | 194.00 (168.94–224.61) | 0.006 |
| Albumin (g/L) | 40.70 (35.33–44.70) | 39.60 (33.02–43.51) | 41.96 (37.49–45.80) | 0.045 |
| Total bilirubin (µmol/L) | 16.53 (11.63–25.24) | 17.60 (12.20–27.70) | 15.39 (11.37–23.20) | 0.165 |
| Bile acids (µg/mL) | 11.00 (5.18–30.00) | 14.30 (6.30–34.20) | 8.70 (4.26–23.88) | 0.002 |
| Total cholesterol (mmol/L) | 4.25 (3.55–5.01) | 4.19 (3.50–4.92) | 4.37 (3.61–5.10) | 0.517 |
| Triglycerides (mmol/L) | 1.06 (0.73–1.53) | 1.02 (0.73–1.44) | 1.12 (0.74–1.71) | < 0.001 |
| HDL-C (mmol/L) | 1.15 (0.90–1.41) | 1.19 (0.91–1.43) | 1.12 (0.89–1.38) | 0.029 |
| LDL-C (mmol/L) | 2.40 (1.87–2.98) | 2.27 (1.76–2.89) | 2.51 (1.95–3.10) | 0.018 |
| apoA (g/L) | 1.19 (1.01–1.38) | 1.14 (0.99–1.27) | 1.18 (1.02–1.39) | 0.849 |
| apoB (g/L) | 0.87 (0.70–1.06) | 0.84 (0.69–1.01) | 0.91 (0.73–1.10) | 0.002 |
| Steatosis | 163 (10.2) | 25 (3.1) | 138 (17.5) | < 0.001 |
| HBeAg sero-positive | 661 (41.2) | 460(56.4) | 201 (25.5) | < 0.001 |

HBV: Chronic hepatitis B virus; FBG: Fasting blood glucose; ALT: Alanine Aminotransferase; AST: Aspartateaminotransferase; ALP: Alkaline Posphatase; LDH: lactic dehydrogenase; HDL: High density lipoprotein; LDL: Low- density lipoprotein; apo-A: Apolipoprotein-A; apo-B: Apolipoprotein-B.

**Table 2 Clinical characteristics of HBeAg-seropositive and HBeAg-seronegative patients with high and low viral load using 104 copies per mL as the cutoff point, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Factors** | **HBeAg sero-positive** | | | **HBeAg sero-negative** | | |
| **High HBV DNA** | **Low HBV DNA** | ***P* value** | **High HBV DNA** | **Low HBV DNA** | ***P* value** |
| **Case *n* = 460** | **Case *n* = 201** | **Case *n* = 355** | **Case *n* = 587** |
| Demographic |  |  |  |  |  |  |
| Age (yr) | 45 (36–59) | 50 (40–59) | 0.106 | 54 (45–61) | 55(46–61) | 0.564 |
| Male gender | 314 (68.2) | 137 (68.1) | 0.412 | 128 (56.6) | 93 (68.4) | 0.026 |
| **Laboratory tests** |  |  |  |  |  |  |
| FBG (mmol/L) | 4.83 (4.40–5.35) | 5.10 (4.60–5.90) | < 0.001 | 5.23 (4.73–6.20) | 5.28 (4.80–6.06) | 0.795 |
| ALT (U/L) | 83.21 (43.45–190.62) | 51.60 (26.62–120.07) | < 0.001 | 53.00 (3200–127.00) | 27.60 (19.38–53.60) | < 0.001 |
| AST (U/L) | 59.30 (38.01–130.1) | 46.85 (26.00–93.18) | < 0.001 | 46.50 (37.57–116.55) | 27.00 (20.72–46.47) | < 0.001 |
| ALP (U/L) | 87.50 (67.98–117.09) | 90.18 (67.00–127.15) | 0.489 | 83.40 (65.20–111.90) | 74.00 (60.00–96.00) | < 0.001 |
| γ-GGT (U/L) | 64.61 (33.50–139.92) | 68.25 (33.25–145.87) | 0.615 | 52.00 (21.90–115.69) | 69.6 (33.40–164.30) | < 0.001 |
| LDH (U/L) | 195.00 (171.92–238.32) | 193.40 (167.37–228.97) | 0.38 | 197.00 (170.08–239.14) | 194.00 (169.00–222.39) | 0.077 |
| Albumin (g/L) | 39.40 (32.81–43.36) | 40.30 (34.89–44.50) | 0.026 | 54.00 (45.00–61.50) | 43.90 (38.00–47.70) | < 0.001 |
| Total bilirubin (µmol/L) | 17.90 (12.40–28.35) | 17.80 (13.21–32.52) | 0.751 | 17.20 (11.9–27.00) | 14.71 (11.08–22.47) | < 0.001 |
| Bile acids (ug/mL) | 16.60 (8.01—38.77) | 16.50 (8.01–41.52) | 0.904 | 10.06 (4.98–27.50) | 7.07 (3.73–16.54) | < 0.001 |
| Total cholesterol (mmol/L) | 4.16 (3.50–4.85) | 4.00 (3.30–4.83) | 0.674 | 4.22 (3.49–5.01) | 4.46 (3.71–5.15) | 0.019 |
| Triglycerides (mmol/L) | 1.03 (0.73–1.44) | 1.08 (0.71–1.71) | 0.429 | 1.04 (0.73–1.41) | 1.14 (0.75–1.72) | 0.002 |
| HDL-C (mmol/L) | 1.19 (0.90–1.43) | 1.08 (0.81–1.40) | 0.041 | 1.20 (0.92–1.44) | 1.12 (0.91–1.38) | 0.13 |
| LDL-C (mmol/L) | 2.25 (1.76–2.90) | 2.41 (1.89–3.06) | 0.041 | 2.31 (1.72–2.87) | 2.54 (1.97–3.12) | < 0.001 |
| apoA (g/L) | 1.17 (0..97–1.35) | 1.15 (0.92–1.30) | 0.204 | 1.21 (1.00–1.40) | 1.20 (1.04–1.41) | 0.624 |
| apoB (g/L) | 0.85 (0.69–1.02) | 0.91 (0.70–1.12) | 0.01 | 0.83 (0.68–1.00) | 0.91 (0.74–1.09) | < 0.001 |
| Steatosis | 11 (2.4) | 37 (18.4) | < 0.001 | 11 (3.0%) | 101 (17.2) | < 0.001 |

HBV: Chronic hepatitis B virus; FBG: Fasting blood glucose; ALT: Alanine Aminotransferase; AST: Aspartateaminotransferase; ALP: Alkaline Posphatase; LDH: Lactic dehydrogenase; HDL: High density lipoprotein; LDL: Low- density lipoprotein; apo-A: Apolipoprotein-A; apo-B: Apolipoprotein-B.

**Table 3** **Results of univariate and multivariate analyses on lipid level and steatosis and chronic hepatitis B viru deoxyribonucleic acid load**

|  |  |  |
| --- | --- | --- |
|  | ***P*** **value** | **OR (95%CI)** |
| **HBsAg sero**-**positive** | |  |
| Steatosis | < 0.001 | 0.15 (0.10–0.23) |
| Triglyceride | 0.027 | 0.83 (0.70–0.98) |
| apoA | 0.009 | 0.47 (0.26–0.83) |
| apoB | 0.905 | 0.99 (0.91–1.08) |
| Cholesterol | 0.009 | 1.39 (1.09–1.77) |
| HDL-C | 0.171 | 1.38 (0.87–2.18) |
| LDL-C | < 0.001 | 0.59 (0.45–0.77) |
| **HBeAg sero**-**positive** | |  |
| Steatosis | < 0.001 | 0.11 (0.05–0.22) |
| Triglyceride | 0.077 | 0.74 (0.53–1.03) |
| apoA | 0.846 | 1.10 (0.41–2.96) |
| apoB | 0.5 | 0.69 (0.23–2.02) |
| Cholesterol | < 0.001 | 2.33 (1.55–3.51) |
| HDL-C | 0.204 | 0.61 (0.29–1.30) |
| LDL-C | < 0.001 | 0.38 (0.24–0.60) |
| **HBeAg sero**-**negative** | |  |
| Steatosis | < 0.001 | 0.19 (0.11–0.35) |
| Triglyceride | 0.002 | 0.69 (0.55–0.87) |
| apoA | 0.209 | 0.62 (0.29–1.31) |
| apoB | 0.713 | 1.02 (0.91–1.14) |
| Cholesterol | 0.004 | 1.69 (1.19–2.40) |
| HDL-C | 0.904 | 0.96 (0.51–1.81) |
| LDL-C | < 0.001 | 0.46 (0.31–0.67) |

HBV: Chronic hepatitis B virus; FBG: Fasting blood glucose; ALT: Alanine Aminotransferase; AST: Aspartateaminotransferase; ALP: Alkaline Posphatase; LDH: Lactic dehydrogenase; HDL: High density lipoprotein; LDL: Low- density lipoprotein; apo-A: Apolipoprotein-A; apo-B: Apolipoprotein-B.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**